Medicare GLP-1 obesity drug coverage delayed indefinitely, interim programme extended
CMS reversal leaves Lilly and Novo Nordisk facing prolonged uncertainty over the largest potential payer expansion for their weight-loss drugs.
Briefing
- •The Trump administration has shifted course on Medicare GLP-1 coverage, indefinitely delaying a pilot programme that would have provided broad obesity drug access to beneficiaries.
- •An interim coverage programme has been extended in its place, meaning Medicare patients retain some subsidised access but under the more limited existing framework.
- •Analysts cited in Reuters suggest near-term demand is unlikely to be materially affected by the delay, given the interim programme remains active.
- •UnitedHealth flagged operational and financial challenges associated with the Medicare obesity drug pilot, signalling insurer-level concerns about cost management.
- •CVS and Amazon have been identified as additional competitive pressures on Eli Lilly and Novo Nordisk in the GLP-1 market, compounding the policy uncertainty.
Analysis
- →The indefinite delay removes the largest near-term volume catalyst for LLY and NVO in the US market. Medicare represents roughly 20% of the US population, and the shift from a broad pilot to an extended interim framework caps the addressable insured demand pool. Competitive pressure from CVS and Amazon pharmacy channels compounds this by compressing the margin available on volumes that do clear through existing coverage, rather than expanding overall unit demand.
- →UnitedHealth's explicit flagging of cost management concerns around the Medicare GLP-1 pilot, now that the programme is delayed, removes a near-term earnings headwind for large managed care insurers. UNH and peers had been pricing in potential medical loss ratio deterioration from broad obesity drug coverage. The delay provides actuarial relief, but the policy remains unresolved, keeping medium-term cost trajectory uncertain and preventing insurers from releasing reserves tied to that exposure.
Historical Context
- Jan 2025
The Biden administration finalized a rule extending Medicare GLP-1 obesity coverage, estimated to cost over $35bn over ten years. The Trump administration's reversal of that rule created the policy vacuum now filled by the interim programme extension, directly setting up the current indefinite delay.
- 2022-2023
CMS initially excluded GLP-1 drugs for obesity under Medicare Part D due to a statutory prohibition on covering weight-loss drugs. Congressional and regulatory efforts to close this gap established the precedent for pilot structures, making the current interim framework a continuation of that workaround rather than a stable long-term solution.
